Skip to main content

Market Overview

Axon Seeks Continued Delay In Digital Ally Case With Another PTO Petition

Axon Seeks Continued Delay In Digital Ally Case With Another PTO Petition

Axon Enterprise Inc (NASDAQ: AAXN) is undeterred by recent setbacks in the everlasting Digital Ally, Inc. (NASDAQ: DGLY) conflict.

The U.S. Patent and Trademark Office denied Axon’s petitions for inter partes review of Digital Ally’s ‘452 patent in July, shortly after issuing Axon a favorable ruling on the ‘292 patent. The USPTO ultimately determines the validity of Digital Ally’s lawsuit surrounding body camera technology.

“The most recent IRP denial has no bearing on the litigation as Digital previously withdrew Claim 1 of the ‘452 patent from the district court case,” Steve Tuttle, Axon vice president of strategic communications, told Benzinga.

Related Link: Analyst Sees ‘Limited Impact’ On Digital Ally From Axon’s Free Body Cam Promotion

With one claim off the table, then, Axon is now pushing to clear additional complaints. This week, it filed a petition for the USPTO to rehear its IPR regarding Claim 10 of the '452 patent.

The last USPTO petition prompted a stay in litigation, with the district court judge vacating future dates pending resolution of outstanding motions. Tuttle anticipates the delay to remain in effect as the latest petition and IPRs on claims for the '292 patent remain pending.

The case involves the automatic activation and coordination of police recording technology.


Related Articles (DGLY + AAXN)

View Comments and Join the Discussion!

Posted-In: '292 patent '452 patent Steve Tuttle U.S. Patent and Trademark Office USPTONews Legal Exclusives Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at